Chemo Articles Cited in PubMed (National Library of Medicine)

Discussion Board Forums Chemotherapy & More Chemo Articles Cited in PubMed (National Library of Medicine)

Viewing 6 posts - 1 through 6 (of 6 total)
  • Author
    Posts
  • #95197
    sfbaybreeze
    Spectator

    Thanks Mary, I agree that it is encouraging!

    #95196
    bglass
    Moderator

    Tilly,

    Thank you for posting these links. It is positive to see the growing interest by researchers in our rare cancer.

    Regards, Mary

    #95195
    sfbaybreeze
    Spectator

    More citations to articles I discovered in PubMed, apologies if they are duplicated elsewhere. Blessings, Tilly

    1: Bréchon M, et al.
    Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers.
    Invest New Drugs. 2017 Aug 1. doi: 10.1007/s10637-017-0492-6. [Epub ahead of
    print] PubMed PMID: 28762171.
    https://www.ncbi.nlm.nih.gov/pubmed/28762171

    2: Wang M, et al.
    Serum N-glycans outperform CA19-9 in diagnosis of extrahepatic cholangiocarcinoma.
    Electrophoresis. 2017 Jul 28. doi: 10.1002/elps.201700084. [Epub ahead of print]
    PubMed PMID: 28752594.
    https://www.ncbi.nlm.nih.gov/pubmed/28752594

    3: Duffy AG, Makarova-Rusher OV, Greten TF.
    The case for immune-based approaches in biliary tract carcinoma. Hepatology. 2016 Nov;64(5):1785-1791. doi: 10.1002/hep.28635. Epub 2016 Jun 18. Review. PubMed PMID: 27177447; PubMed Central PMCID: PMC5074847. This article will become available for free on 11/1/2017
    https://www.ncbi.nlm.nih.gov/pubmed/27177447

    #95194
    sfbaybreeze
    Spectator

    These are some citations to articles I discovered while searching PubMed, apologies if they are duplicated elsewhere. Blessings, Tilly

    1: Shah UA, Nandikolla AG, Rajdev L. Immunotherapeutic Approaches to Biliary
    Cancer. Curr Treat Options Oncol. 2017 Jul;18(7):44. doi:
    10.1007/s11864-017-0486-9. Review. PubMed PMID: 28660602.
    https://www.ncbi.nlm.nih.gov/pubmed/28660602

    2: Jusakul A, et al. Whole-Genome and Epigenomic Landscapes of
    Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discov. 2017 Jun
    30. pii: CD-17-0368. doi: 10.1158/2159-8290.CD-17-0368. [Epub ahead of print]
    PubMed PMID: 28667006.
    https://www.ncbi.nlm.nih.gov/pubmed/28667006

    3: Du L, Che Z, Wang-Gillam A. Promising therapeutics of gastrointestinal cancers
    in clinical trials. J Gastrointest Oncol. 2017 Jun;8(3):524-533. doi:
    10.21037/jgo.2017.01.08. Review. PubMed PMID: 28736639; PubMed Central PMCID:
    PMC5506268.
    https://www.ncbi.nlm.nih.gov/pubmed/28736639

    4: Zhao DY, Lim KH. Current biologics for treatment of biliary tract cancers. J
    Gastrointest Oncol. 2017 Jun;8(3):430-440. doi: 10.21037/jgo.2017.05.04. Review.
    PubMed PMID: 28736630; PubMed Central PMCID: PMC5506280.
    https://www.ncbi.nlm.nih.gov/pubmed/28736630

    5: Fakhri B, Lim KH. Molecular landscape and sub-classification of
    gastrointestinal cancers: a review of literature. J Gastrointest Oncol. 2017
    Jun;8(3):379-386. doi: 10.21037/jgo.2016.11.01. Review. PubMed PMID: 28736626;
    PubMed Central PMCID: PMC5506283.
    https://www.ncbi.nlm.nih.gov/pubmed/28736626

    #95193
    marions
    Moderator

    You are in the right place. Thanks for posting this for us.

    Hugs
    Marion

    #13467
    sfbaybreeze
    Spectator

    These are some citations to articles I discovered while searching PubMed and I wanted to share them with the community. Unfortunately the full texts of these articles aren’t available for free but at least the abstracts in PubMed have information. I hope I’m posting this in the right place. Moderators, please let me know if these should go elsewhere. Blessings!

    Mitin T, Enestvedt CK, Jemal A, Sineshaw HM.
    Limited Use of Adjuvant Therapy in Patients With Resected Gallbladder Cancer Despite a Strong Association With Survival.
    J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw324.
    PubMed PMID: 28376178.

    https://www.ncbi.nlm.nih.gov/pubmed/28376178

    Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Cho H, Ryoo BY, Chang HM.
    Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
    Cancer Chemother Pharmacol. 2017 Jun 8. doi: 10.1007/s00280-017-3353-2. [Epub ahead of print]
    PubMed PMID: 28597043.

    https://www.ncbi.nlm.nih.gov/pubmed/28597043

    Cho KM, Park H, Oh DY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ.
    Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.
    Oncotarget. 2017 Jun 2. doi: 10.18632/oncotarget.18345. [Epub ahead of print]
    PubMed PMID: 28621674.

    https://www.ncbi.nlm.nih.gov/pubmed/28621674

Viewing 6 posts - 1 through 6 (of 6 total)
  • The forum ‘Chemotherapy & More’ is closed to new topics and replies.